BioCryst Pharmaceuticals provided insights in their Q3 2024 earnings call. The company emphasized continued growth in Orladeyo revenue and confidence in reaching sustainable profitability. They discussed adding new prescribers, progress towards achieving a paid rate of 85%, and potential competition in the market.